Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 31, 2004. The document primarily reports on corporate actions regarding share buybacks and updates on directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data presented relates to specific share transactions:
- Share Buyback (March 29): 450,000 shares purchased at 1,074.1179 pence per share.
- Share Buyback (March 30): 450,000 shares purchased at 1,075.2907 pence per share.
- Treasury Shares: Total holdings increased to 9,270,000 shares following the March 30 transaction.
- Shares in Issue: 5,925,300,921 shares (excluding Treasury shares) as of March 30, 2004.
- ADR Fund Movement: The GlaxoSmithKline US Retirement Savings Plan held 18,906,970 ADRs at an average price of $39.80.
Material Changes
The primary material changes reported are the reduction in outstanding shares due to treasury purchases and minor adjustments in directors' beneficial interests:
- Treasury Holdings: Increased from 8,820,000 to 9,270,000 shares over two consecutive days.
- Directors' Interests: Minor acquisitions of beneficial interests by Sir Christopher Hogg, Mr. J.D. Coombe, Mrs. G.A. Coombe, and Sir Peter Job via Personal Equity Plans.
- Employee Trusts: Transfers of shares from the SmithKline Beecham Employee Benefit Trust to participants in bonus and annual investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of share transactions and director disclosures.
Key Facts for Investor Verification
- Verify the total cost of the 900,000 shares repurchased in late March 2004 against the company's cash position in the full quarterly report.
- Confirm the impact of the increased treasury share count (9,270,000) on earnings per share calculations in subsequent filings.
- Review the full Annual Report (Form 20-F) for the comprehensive financial performance metrics absent from this 6-K.